Minerva Neurosciences Inc 603380205 US6033802058 12/22/2025 To approve, on an advisory basis, the compensation of the Company's named executive offi cers, as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 1419000 0 FOR 1419000 FOR Amicus Therapeutics Inc 03152W109 US03152W1099 03/03/2026 To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to Amicus' named executive officers that is based on or otherwise relates to the Merger. SECTION 14A SAY-ON-PAY VOTES 661293 132020 FOR 661293 FOR X4 Pharmaceuticals Inc 98420X202 US98420X2027 05/11/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 2571478 0 FOR 2571478 FOR Nurix Therapeutics Inc 67080M103 US67080M1036 05/15/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 1412367 330853 FOR 1412367 FOR Opus Genetics Inc 67577R102 US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES 500000 0 FOR 500000 FOR Cytokinetics Inc 23282W605 US23282W6057 05/27/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 300000 0 FOR 300000 FOR Mirum Pharmaceuticals Inc 604749101 US6047491013 06/15/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 333312 0 FOR 333312 FOR 4D Molecular Therapeutics Inc 35104E100 US35104E1001 06/17/2026 Approval, on an advisory, non- binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote"). SECTION 14A SAY-ON-PAY VOTES 453014 1076452 FOR 453014 FOR Immunocore Holdings PLC 45258D105 US45258D1054 05/27/2026 To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the attached proxy statement. SECTION 14A SAY-ON-PAY VOTES 179897 502700 FOR 179897 FOR Minerva Neurosciences Inc 603380205 US6033802058 06/03/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 1419000 0 FOR 1419000 FOR Minerva Neurosciences Inc 603380205 US6033802058 06/03/2026 To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 1419000 0 FOR 1419000 FOR Neurogene Inc 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non- binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 402535 380252 FOR 402535 FOR Neurogene Inc 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the company to its named executive officers should be held every one, two or three years. SECTION 14A SAY-ON-PAY VOTES 402535 380252 FOR 402535 FOR Vaxcyte Inc 92243G108 US92243G1085 06/15/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 293470 0 FOR 293470 FOR Arcus Biosciences Inc 03969F109 US03969F1093 06/11/2026 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 1134935 0 FOR 1134935 FOR Syndax Pharmaceuticals Inc 87164F105 US87164F1057 06/10/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement. SECTION 14A SAY-ON-PAY VOTES 640898 259102 FOR 640898 FOR Xenon Pharmaceuticals Inc 98420N105 CA98420N1050 06/02/2026 To approve, on an advisory basis, the compensation of the Corporation's named executive officers. SECTION 14A SAY-ON-PAY VOTES 440000 0 FOR 440000 FOR Xenon Pharmaceuticals Inc 98420N105 CA98420N1050 06/02/2026 To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers. SECTION 14A SAY-ON-PAY VOTES 440000 0 FOR 440000 FOR Revolution Medicines Inc 76155X100 US76155X1000 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES 132750 0 FOR 132750 FOR Forte Biosciences Inc 34962G208 US34962G2084 05/29/2026 The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote"). SECTION 14A SAY-ON-PAY VOTES 185000 0 FOR 185000 FOR Inhibikase Therapeutics Inc 45719W205 US45719W2052 06/26/2026 to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 8079415 0 FOR 8079415 FOR Inhibikase Therapeutics Inc 45719W205 US45719W2052 06/26/2026 to vote, on a non-binding, advisory basis, on the frequency of future non-binding, advisory votes on compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 8079415 0 FOR 8079415 FOR vTv Therapeutics Inc 918385204 US9183852048 06/26/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 135511 0 FOR 135511 FOR